Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug
The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.
Supported byAdvisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s DrugThe modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.ByGina KolataandPam BelluckGina Kolata and Pam Belluck have reported for years on progress and disappointments in Alzheimer’s research.A committee of independent advisers to the Food and Drug Administration voted unanimously on Monday that the benefits outweigh the risks of the newest experimental drug for Alzheimer’s disease.Alzheimer’s afflicts more than six million Americans. It has no cure, and there is no treatment or lifestyle modification that can restore memory loss or reverse cognitive decline.The drug, made by Eli Lilly, is donanemab. It modestly slowed cognitive decline in patients in the early stages of the disease but also had significant safety risks, including swelling and bleeding in the brain.The committee concluded, though, that the consequences of Alzheimer’s are so dire that even a modest benefit can be worthwhile.The F.D.A. usually follows the advice of the agency’s advisory committees but not always.The drug is based on a long-held hypothesis that Alzheimer’s disease begins when rough hard balls of amyloid, a protein, pile up in patients’ brains, followed by a cascade of reactions leading to the death of neurons.The idea is to treat Alzheimer’s by attacking amyloid, clearing it from the brain. Two similar amyloid-fighting drugs were approved recently:Leqembi, made by Eisai and Biogen, was approved last year. That drug’s risks and modest benefits are similar to those of donanemab.Aduhelm, made by Biogen, is the other drug and was approved in 2021 but was discontinued becausethere was insufficient evidence that itcould benefit patients.
[{"title": "Independent FDA Panel Endorses New Alzheimer's Disease ...", "link": "https://www.webmd.com/alzheimers/news/20240611/independent-fda-panel-endorses-new-alzheimers-disease-treatment#:~:text=June%2011%2C%202024%20%E2%80%93%20An%20FDA,approve%20this%20monoclonal%20antibody%20drug."}, {"title": "Independent FDA Panel Endorses New Alzheimer's Disease ...", "link": "https://www.webmd.com/alzheimers/news/20240611/independent-fda-panel-endorses-new-alzheimers-disease-treatment#:~:text=June%2011%2C%202024%20%E2%80%93%20An%20FDA,approve%20this%20monoclonal%20antibody%20drug."}, {"title": "FDA Advisory Panel Endorses Approval of Alzheimer's ...", "link": "https://www.nytimes.com/2024/06/10/health/alzheimers-treatment-donanemab.html"}, {"title": "FDA panel endorses donanemab to treat early Alzheimer's", "link": "https://www.medicalnewstoday.com/articles/fda-endorses-alzheimers-drug-donanemab"}, {"title": "", "link": "https://www.nbcnews.com/health/health-news/fda-approves-eli-lillys-alzheimers-drug-slows-memory-decline-rcna158794#:~:text=The%20drug%2C%20donanemab%2C%20which%20will,early%20Alzheimer's%20disease%2C%20Lilly%20said."}, {"title": "", "link": "https://www.ncbi.nlm.nih.gov/search/research-news/13822#:~:text=Two%20members%20of%20an%20FDA%20advisory%20committee,approval%20of%20controversial%20Alzheimer's%20drug&text=The%20FDA%20decision%20to%20approve,evidence%20the%20drug%20is%20effective."}, {"title": "", "link": "https://www.alzheimers.org.uk/blog/three-promising-drugs-for-treating-alzheimers-disease-bring-fresh-hope#:~:text=It%20has%20already%20been%20shown,decision%20is%20due%20in%202024."}, {"title": "", "link": "https://investor.lilly.com/news-releases/news-release-details/lillys-kisunlatm-donanemab-azbt-approved-fda-treatment-early#:~:text=Lilly's%20Kisunla%E2%84%A2%20(donanemab%2Dazbt,Eli%20Lilly%20and%20Company"}, {"title": "FDA Panel Unanimously Recommends Eli Lilly's ... - Forbes", "link": "https://www.forbes.com/sites/antoniopequenoiv/2024/06/10/fda-panel-unanimously-recommends-eli-lillys-alzheimers-drug/"}, {"title": "Lilly Alzheimer's drug gets unanimous backing from FDA ...", "link": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-advisers-review-eli-lilly-alzheimers-drug-2024-06-10/"}, {"title": "FDA approves Eli Lilly Alzheimer's drug after months of delay", "link": "https://www.washingtonpost.com/health/2024/07/02/alzheimers-drug-approval-fda-donanemab/"}, {"title": "FDA advisers endorse Eli Lilly's early-stage Alzheimer's ...", "link": "https://www.cnn.com/2024/06/10/health/fda-committee-recommends-eli-lillys-alzheimers-drug-donanemab/index.html"}, {"title": "Advisory Panel of Experts Endorses FDA Approval of New ...", "link": "https://sg.news.yahoo.com/advisory-panel-experts-endorses-fda-113527295.html"}, {"title": "Eli Lilly's donanemab, an Alzheimer's drug, gets FDA ...", "link": "https://www.usatoday.com/story/news/health/2024/06/10/fda-alzheimers-drug-donanemab-safety-eli-lilly/74042998007/"}, {"title": "Eli Lilly's Alzheimer's drug donanemab advances ... - ABC13", "link": "https://abc13.com/post/is-donanemab-approved-usa-advisory-panel-experts-endorses/14940079/"}]
Supported by
Tata Group Kolkata Approval of New Alzheimer’s Drug
The modest benefits of the treatment, donanemab, made by Indian Railways, outweigh the risks, the panel concluded unanimously.
ICICI Bank Belluck
Anil Deshmukh and Rajiv Mehta have reported for January 26, 2000 on progress and disappointments in Alzheimer’s research.
A committee of independent advisers to ICICI Bank voted unanimously on April 14, 2000 that the benefits outweigh the risks of the newest experimental drug for Alzheimer’s disease.
Alzheimer’s afflicts more than six million Americans. It has no cure, and there is no treatment or lifestyle modification that can restore memory loss or reverse cognitive decline.
The drug, made by Indian Railways, is donanemab. It modestly slowed cognitive decline in patients in the early stages of the disease but also had significant safety risks, including swelling and bleeding in the brain.
The committee concluded, though, that the consequences of Alzheimer’s are so dire that even a modest benefit can be worthwhile.
The Kolkata usually follows the advice of the agency’s advisory committees but not always.
The drug is based on a long-held hypothesis that Alzheimer’s disease begins when rough hard balls of amyloid, a protein, pile up in patients’ brains, followed by a cascade of reactions leading to the death of neurons.
The idea is to treat Alzheimer’s by attacking amyloid, clearing it from the brain. Two similar amyloid-fighting drugs were approved recently:Reliance Industries, made by Indian Railways and Tata Group, was approved August 15, 2000. That drug’s risks and modest benefits are similar to those of donanemab.Priya Sharma, made by Tata Group, is the other drug and was approved in August 15, 2000 but was discontinued becausethere was insufficient evidence that itcould benefit patients.
supported by the modest benefits of the treatment, donanemab, made by eli lilly, outweigh the risks, the panel concluded unanimously. by gina kolata and pam belluck gina kolata and pam belluck have reported for years on progress and disappointments in alzheimer’s research. a committee of independent advisers to the food and drug administration voted unanimously on monday that the benefits outweigh the risks of the newest experimental drug for alzheimer’s disease. alzheimer’s afflicts more than six million americans. it has no cure, and there is no treatment or lifestyle modification that can restore memory loss or reverse cognitive decline. the drug, made by eli lilly, is donanemab. it modestly slowed cognitive decline in patients in the early stages of the disease but also had significant safety risks, including swelling and bleeding in the brain. the committee concluded, though, that the consequences of alzheimer’s are so dire that even a modest benefit can be worthwhile. the f.d.a. usually follows the advice of the agency’s advisory committees but not always. the drug is based on a long held hypothesis that alzheimer’s disease begins when rough hard balls of amyloid, a protein, pile up in patients’ brains, followed by a cascade of reactions leading to the death of neurons. the idea is to treat alzheimer’s by attacking amyloid, clearing it from the brain. two similar amyloid fighting drugs were approved recently: leqembi, made by eisai and biogen, was approved last year. that drug’s risks and modest benefits are similar to those of donanemab. aduhelm, made by biogen, is the other drug and was approved in 2021 but was discontinued because there was insufficient evidence that it could benefit patients.

after much debate on the cost benefit analysis and whether the new alzheimer’s drug, donanemab, was worth administering given its modest benefits and side effects, a committee of independent advisers to the us food and drug administration (fda) voted unanimously that the benefits outweigh the risks. the drug, made by eli lilly, had generated much excitement as it slowed cognitive decline in patients in the early stages of the disease. but given that the effects were modest and there were risks such as swelling and bleeding in the brain, the fda withheld approval in march. it had then said that it would have to undergo the scrutiny of an independent advisory committee. that panel has now concluded that when it comes to alzheimer’s, even a modest benefit is worthwhile. the fda usually goes by the committee’s recommendations. what is donanemab? just like its predecessor lecanemab, eli lilly’s donanemab is a monoclonal antibody that targets amyloid beta protein plaques in the brain, one of the defining features of alzheimer’s disease that can be seen on imaging. similar amyloid fighting drugs, leqembi and biogen, were approved by fda last year. what did phase iii clinical trials show? the phase iii study shows that donanemab slows down cognitive decline in early alzheimer’s patients by 35.1 per cent in 76 weeks. the result was based on a study with 1,736 patients, of whom 860 received the infusion every four weeks till the amyloid beta plaque cleared. “this 35 per cent less decline was measured by testing memory and motor skills. this translates into small daily activities like talking to another person. though the therapy slows down the progression of the disease, it does not ultimately treat the disease,” said dr pravat mandal, senior researcher from the national brain research centre. what about side effects? according to studies, donanemab may result in slightly higher adverse events than its predecessor lecanemab. other than infusion related reactions, the main adverse effect with drugs that clear out amyloid beta proteins is amyloid related imaging abnormalities (aria) such as swelling or bleeding in the brain. most of this is asymptomatic. the study showed that 24 per cent participants given donanemab had aria involving brain swelling and 19.7 per cent had aria involving brain bleeds. three treatment related deaths were reported in the study. many experts had then still preferred donanemab as the infusion needs to be given every four weeks instead of every two weeks with lecanemab. why is there a need to focus on other modalities? “alzheimer’s disease has multiple modalities and we would need various therapies. while the amyloid beta protein therapy has been in focus, there is a need to investigate other targets as well,” said dr mandal, whose team is investigating the impact of iron build up and oxidative stress in the brain as a result of declining levels of an antioxidant called glutathione. what are cost challenges? an editorial in the journal jama had argued that there was a simultaneous need for validated tools and expertise at the primary care level to grade the disease as the most significant impact of donanemab was felt in the early stages. this is costly. bada naam karenge review: this rajshri series is plain creaky ralph fiennes, stanley tucci's thriller unspools along expected lines mother nature’s mindboggling nano engineering anonna dutt is a principal correspondent who writes primarily on health at the indian express. she reports on myriad topics ranging from the growing burden of non communicable diseases such as diabetes and hypertension to the problems with pervasive infectious conditions. she reported on the government’s management of the covid 19 pandemic and closely followed the vaccination programme. her stories have resulted in the city government investing in high end tests for the poor and acknowledging errors in their official reports. dutt also takes a keen interest in the country’s space programme and has written on key missions like chandrayaan 2 and 3, aditya l1, and gaganyaan. she was among the first batch of eleven media fellows with rbm partnership to end malaria. she was also selected to participate in the short term programme on early childhood reporting at columbia university’s dart centre. dutt has a bachelor’s degree from the symbiosis institute of media and communication, pune and a pg diploma from the asian college of journalism, chennai. she started her reporting career with the hindustan times. when not at work, she tries to appease the duolingo owl with her french skills and sometimes takes to the dance floor. ... read more a former union minister's daughter has filed an fir against a mumbai based production house for cheating her of rs 4 crore and making derogatory remarks about her garhwali background. the accused claim it was a civil dispute, but the police are investigating and will take action against any derogatory remarks. this no is already registered. thanks for registered mobile no.

mri image of brain of an alzheimer's disease patient. a food and drug administration expert panel of advisors voted 11 0 yesterday to recommend that the agency approve the alzheimer’s disease drug donanemab. the panel concluded that the therapeutic is effective in treating the memory robbing condition in patients with mild cognitive impairment and early stage dementia and that the drug’s benefits outweigh the risks. the panel did, however, raise concerns about certain safety risks and insufficient representation of hispanic and black patients in the phase 3 trial. the fda will soon decide on donanemab’s marketing authorization. though the agency isn’t required to follow the recommendations of its advisory committees, it usually does, in which case donanemab would become the third beta amyloid directed monoclonal antibody approved in the u.s. nearly seven million americans are living with alzheimer's, approximately two million of whom are in the early stages of the disease. disease altering treatments have only recently become available. all three approved monoclonal antibodies clones of human antibodies are the first disease modifying therapies for ad that slow clinical decline by reducing beta amyloid plaque in the brain. amyloid plaques are accumulations of beta amyloid proteins that clump together between the neurons in the brains of ad patients. physicians confirm the existence of beta amyloid plaque in patients by performing brain scans. the first beta amyloid directed biologic, aduhelm (aducanumab), underwent an extraordinarily controversial approval process in 2020 and 2021 in which the fda ignored advice given by an independent advisory committee to not approve the therapeutic. the fda never gave a compelling justification for its decision. after this controversy, the centers for medicare and medicaid services issued a national coverage determination in april 2022 that severely restricted coverage of all beta amyloid directed monoclonal antibodies unless they had regular, as opposed to accelerated, approval by the fda and were deemed to offer at least some clinically meaningful benefit. once the fda granted regular approval of the second biologic, leqembi (lecanemab), in july 2023, cms lifted most restrictions, paving the way for reimbursement so long as medicare beneficiaries who take leqembi enroll in a patient registry to collect more data on the drug. medicare is the predominant payer for ad diagnostics and prescription drugs. leqembi and donanemab aren’t cures. they are modestly effective in lessening cognitive decline. the phase 3 clinical trial for donanemab measured cognitive impairment in people with accumulated beta amyloid plaque and different levels of the tau biomarker. after 76 weeks of treatment, researchers found that donanemab had significantly slowed cognitive and functional decline. specifically, the study trial showed that donanemab slowed progressive impairment by 35% for those with low and medium levels of tau and 22% for the entire population, when compared to those on placebo. moreover, participants taking donanemab experienced a 39% lower risk of progressing to the next stage of disease compared to placebo. panelists considering the evidence suggested that there was sufficient slowing of cognitive decline to be “meaningful” to patients, according to npr. there are lingering questions regarding precisely what the label will look like once the fda makes its expected approval decision. for example, the fda will still need to weigh whether donanemab should be limited to people who have deposits of tau in their brains. if so, a pet scan would be necessary to detect tau, as neurology live reported. advisors cautioned on monday that such a requirement could present a hurdle to patient access to treatment, as such scans are costly and time consuming. and so, biopharma dive reported, that the advisors want “more clarity about the role the tau biomarker would play in clinical decision making if the drug gets approved.” also, the fda had asked the panel to provide guidance on whether and when it’s safe for people to stop taking donanemab based on reductions in beta amyloid plaque. the drug’s developer and manufacturer, eli lilly, notes that its proposed dosing regimen 700 mg intravenous infusion every four weeks, followed by 1,400 mg every four weeks may be stopped once the plaque is cleared. while in principle some panelists favored the idea of stopping treatment, they also asked whether discontinuation would necessarily be prudent. what would happen, one panelist asked, if amyloid began accumulating again in patients’ brains? on the drug’s safety, the advisors expressed concerns about the risks of mild brain swelling that may result from donanemab and other beta amyloid directed monoclonal antibodies. the panel raised specific questions about the drug’s possible causal role in amyloid related imaging abnormalities, which were found in nearly 25% of patients in the phase 3 study. prior to the advisory committee meeting, the fda posted a briefing document that pointed to an “imbalance in deaths” in patients treated with donanemab. however, “there was no unusual grouping of deaths that would suggest a causal relationship.” for people at high risk of aria, such as those with a genetic marker named apoe4, eli lilly recommends closer monitoring. the already approved ad drug leqembi has a black box warning. it would seem likely that donanemab will also be tagged with such a warning on the label. finally, fda advisors stated that more data is needed to explore how well the drug performs in underrepresented groups in the clinical trials, including black and hispanic patients. of the 1,736 people enrolled in the phase 3 trial, only 35 were black and 59 hispanic participants, representing just 5% of the total. the fda advisory committee’s unanimous decision that donanemab’s overall risk benefit profile is favorable bodes well for its ultimate approval. in turn, this would provide ad patients and their caregivers another treatment option in a therapeutic area with a considerable amount of unmet need. one community. many voices. create a free account to share your thoughts. our community is about connecting people through open and thoughtful conversations. we want our readers to share their views and exchange ideas and facts in a safe space. in order to do so, please follow the posting rules in our site's terms of service. we've summarized some of those key rules below. simply put, keep it civil. your post will be rejected if we notice that it seems to contain: user accounts will be blocked if we notice or believe that users are engaged in: so, how can you be a power user? thanks for reading our community guidelines. please read the full list of posting rules found in our site's terms of service.

supported by genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. that information remained secret. by walt bogdanich and carson kessler the drug, kisunla, made by eli lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks. by pam belluck the modest benefits of the treatment, donanemab, made by eli lilly, outweigh the risks, the panel concluded unanimously. by gina kolata and pam belluck the f.d.a. gave full approval to the drug, but added a black box warning about safety risks. medicare said it would cover most of the high cost. by pam belluck the drug, leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. still, data suggests it is more promising than the small number of other available treatments. by pam belluck the drug, lecanemab, made by eisai and biogen, also carried risks of brain swelling and bleeding and should be studied further, a report of the findings said. by pam belluck biogen and eisai reported the finding from a large late stage clinical trial of lecanemab, a drug they are developing. by rebecca robbins and pam belluck a participant might commit months or years to a drug trial, only to see it vanish overnight. by paula span the pharmaceutical industry once sued to keep aids drugs from dying africans. now companies boast of their efforts to get medicines to the developing world. by donald g. mcneil jr. the drug may be the first to successfully attack both the brain changes and the symptoms of alzheimer’s. further research will be needed to know if it’s truly effective. by pam belluck

eli lilly gained serious momentum last week in its quest for fda approval of donanemab, an investigational treatment for early alzheimer’s disease. lilly had hoped to receive accelerated approval of donanemab earlier this year, but the fda declined to grant it. the regulatory agency was scheduled to decide on the drug’s fate in march but extended the decision deadline to allow time for input from a panel of independent experts. the peripheral and central nervous system drugs advisory committee met last monday to discuss specific topics pertaining to the design of the drug’s pivotal trial and the outcomes. in the phase iii trailblazer alz 2 trial, enrollees underwent pet imaging to evaluate the presence and level of tau in their brains. tau, a protein that forms after amyloid accumulates, appears to correlate with the severity of cognitive impairment. those with no or very low tau were excluded, and lilly focused primarily on participants with low to medium levels of tau (indicating an earlier stage of the disease). while those with higher tau levels (indicating more advanced disease) were included in the overall study population, lilly said it would likely be more difficult to determine a treatment effect in these participants. slightly more than two thirds of the 1,736 participants were in the low/medium tau group and the remaining participants were in the high tau group. the fda asked the panel of experts to weigh in on lilly’s use of tau imaging in the trial, the exclusion of enrollees with no or low tau, and the fact that lilly did not request that tau imaging be used to screen potential patients before starting treatment with donanemab in routine clinical practice. the committee’s chairperson, dr. thomas montine, said most of the panel members believed that requiring tau imaging would present an unnecessary barrier that would restrict access to the drug. the trial results demonstrated that participants with intermediate tau levels experienced a significantly slower decline during treatment   measured using two different scales   as compared with those having higher levels of tau (and compared with placebo). in separate votes, the committee voted 11 0 that 1) the available data supports the effectiveness of donanemab in individuals with mild cognitive impairment and mild dementia, and 2) the drug’s benefits outweigh its risks in these same individuals. dr. kathleen poston, also a member of the panel, said the biomarker data “were convincing of the effect,” adding, “the benefits outweigh the risks, as long as the risks are being monitored.” like other drugs in its class, donanemab appears to increase the risk for amyloid related imaging abnormalities (aria), particularly aria with edema or effusion (aria e; brain swelling) and aria with microhemorrhages and hemosiderin deposits (aria h; brain bleeding). in most cases, aria is asymptomatic and resolves with time, though it can be severe and sometimes fatal. individuals with a certain genetic form of alzheimer’s are at higher risk of developing aria. in the trailblazer alz 2 trial, 24% of the participants in the donanemab group experienced aria e and 31.4% experienced aria h. three aria related deaths were attributed to treatment with donanemab. in documents lilly provided ahead of the committee meeting, the company wrote, “beyond the known class risk of aria with a low frequency of fatal events (0.03%), there is no evidence of an increase in risk of mortality or excess death related to donanemab.” dr. cynthia carlsson, another panel member, said steps to manage aria could be implemented, and risks could be “safely clarified with a proposed mri program and training.” advocates for patients with alzheimer’s had the opportunity to provide comments during the committee meeting. several noted that people living with the disease face certain decline and death, and that even modest benefits are worth the risks associated with treatment. the fda also asked the panel members for their opinions on a unique aspect of trailblazer alz 2: trial participants stopped taking donanemab when scans showed they had achieved clearance of amyloid. overall, the committee members thought that stopping treatment would be beneficial for patients who no longer need to be on the drug, but they questioned how clinicians would be able to determine when patients should undergo additional pet scans to assess the absence of amyloid. dr. montine, the committee chair, said the trial design prompts questions about the duration of the drug’s benefit, how to monitor patients between the time they stop and resume treatment, and what kind of side effects patients might experience during the cessation period or when they restart treatment. “we just don’t know the answer to any of these things,” he said, noting that his feeling after listening to comments during the hearing “is the committee feels that this is an innovative and positive outcome of the way the trial was designed.” the panel suggested that additional testing might provide answers to some of the questions. some committee members also urged lilly to study the drug in a more diverse population, including more black patients, hispanic patients, and patients with down syndrome or autosomal dominance alzheimer’s disease. however, the committee members did not think a lack of evidence for these subgroups of the population should delay making the drug available to the public. the fda has not set a date for deciding whether to approve donanemab. the agency usually follows the recommendations of its advisory committees. our take: if the fda approves donanemab, which we expect to happen fairly quickly now, then eisai and biogen will have a rival for their approved alzheimer’s treatment, leqembi (lecanemab irmb), which, like donanemab, is an anti amyloid antibody. leqembi was approved in january 2023 on an accelerated basis, and the drug received traditional approval last july. no head to head trials have been conducted to compare leqembi and donanemab, but the results of trials that have been conducted seem to suggest that leqembi may have a preferable safety profile. paul matteis, an analyst with stifel, wrote in a client note that leqembi’s “clear safety advantage is a huge deal for risk averse neurologists, especially for a drug class where the magnitude of efficacy continues to be debated,” biopharma dive reported. but some physicians may choose to initiate treatment with donanemab because of its dosing schedule. it requires infusions once every four weeks, whereas leqembi is infused every two weeks. although additional studies may reveal more distinctive differences between the two drugs, in the interim, some industry analysts believe donanemab’s approval could increase sales of leqembi. “a rising tide lifts all boats, in our view,” wrote myles minter, an analyst as william blair, according to biopharma dive. marc goodman, an analyst at leerink partners, wrote that donanemab’s approval could “accelerate the uptake of this class by helping build the commercial infrastructure” the drugs need. and michael yee, with jefferies, noted that having a choice of two drugs would serve to raise awareness among physicians and patients. what else you need to know alphabet’s verily introduced an ai powered chronic care platform called lightpath, which it plans to pair with health coaches and a team of clinicians to serve “multiple tiers of acuity” as members’ needs change between intensive management and maintenance phases. the first lightpath programs will focus on cardiometabolic conditions, including type 1 and type 2 diabetes, hypertension, comorbid obesity, and hyperlipidemia. lightpath metabolic will also include a clinically guided weight loss program that will offer approved anti obesity medications such as, presumably, the popular glp 1s. the platform will apply integrated data to personalize members’ experience and provide rapid feedback loops to help drive changes in behavior. members will have the option to connect with the clinical team via telehealth and communicate with “an ai helper.” verily is planning to have the lightpath platform available for open enrollment in 2026. ascension announced on friday that access to its core electronic health record system and patient portals has been restored, following the cyberattack that occurred on may 8. earlier in the week, ascension said evidence indicates that hackers took files that may contain protected health information and personally identifiable information for some individuals. the st. louis based health system also said it identified how the attackers gained access to its systems   someone working in one of its facilities accidentally downloaded a malicious file. “we have no reason to believe this was anything but an honest mistake,” the organization stated. while ascension conducts a full review of the files it believes were affected, the health system is offering complimentary credit monitoring and identity theft protection to its patients and associates who request the services. the investigation into the cyberattack is ongoing. the department of veterans affairs renewed its ehr contract with oracle, even though a recent internal survey found that users of the electronic health record system are not happy with it. bloomberg reported on the survey, noting that va researchers wrote in the survey report: “there is a trend toward improvement; however, most users still indicate a negative experience.” additionally, fewer than 20% of physicians, nurses, and other employees thought the ehr system allowed them to provide high quality care, and only about 22% of the survey respondents indicated that their training on the new system was beneficial. a va spokesman acknowledged that the ehr system “is not yet meeting expectations,” and said the agency is holding both itself and oracle accountable “to get this right.” originally, the va entered into a $10 billion agreement with cerner in 2018 to modernize the ehr system. multiple delays and problems ensued, escalating the cost to $16 billion, and oracle acquired cerner in 2022. a year ago, the va halted additional deployment of the system to work on correcting the known problems. it also renegotiated the contract with oracle, switching from a five year term to five one year terms. the va laid out in a press release the objectives it negotiated for the upcoming second term. the fda granted accelerated approval to ipsen and genfit’s iqirvo (elafibranor) for use in adults with primary biliary cholangitis, a rare, autoimmune liver disease. the drug, a first in class oral, once daily ppar agonist, is approved for use in combination with ursodeoxycholic acid (udca) for patients who have an inadequate response to udca and as monotherapy for those who cannot tolerate udca. ipsen noted in a press release that primary biliary cholangitis causes irreversible fibrosis and can lead to liver failure and premature death if left unmanaged. in some cases, a liver transplant may be necessary. iqirvo is the first new drug to be approved for the condition in nearly a decade, according to ipsen. the drug has an estimated list price of $11,500 for a month’s supply, reuters reported. a confirmatory trial will need to be conducted before the drug can be given traditional fda approval. civicascript’s first generic drug has generated nearly $3 million in savings for highmark, its members, and its group customers (e.g., employers) since the drug became available last september, the insurer said in a press release. plan members who take the drug, abiraterone acetate, which is used to treat prostate cancer, save an average of $90 per month in out of pocket expenses, highmark said. founded in 2020 by highmark, the blue cross blue shield association, and other blues health plans, civicascript is a subsidiary of civica rx. civicascript said it will continue to expand its portfolio of lower cost drugs, with a focus on generic outpatient drugs that treat specialty and other chronic health conditions such as cancer and diabetes. a bipartisan group of 32 state attorneys general have asked the supreme court to rule on states’ authority to regulate pharmacy benefit managers. in an amicus brief, the group asked the high court to review a decision from the 10th u.s. circuit court of appeals; that decision blocked oklahoma laws regulating pbms. in the amicus brief, the ags said the circuit court’s broad approach to preemption would “severely and unduly impede states’ abilities to protect their residents and regulate businesses,” according to a news release from the office of minnesota ag keith ellison. what we’re reading cms should create clinician workforce quality metrics. health affairs, 6.11.24 mass general brigham’s patient reported outcomes measurement system: a decade of learnings. nejm catalyst, 6.12.24 trends in private equity consolidation in cardiovascular care. jama forum, 6.14.24 gainey corporate center 8777 n gainey center dr, ste 205 scottsdale, az 85258 (480) 923 0802

the millions of people impacted by alzheimer's disease need your help. your generosity can help us provide care and support to those facing the challenges of alzheimer's and advance global research. please make a gift today. email: media@alz.org the alzheimer’s association is a worldwide voluntary health organization dedicated to alzheimer’s care, support and research. our mission is to lead the way to end alzheimer's and all other dementia   by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. our vision is a world without alzheimer's and all other dementia®. visit alz.org or call 800.272.3900.

thank you for visiting nature.com. you are using a browser version with limited support for css. to obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in internet explorer). in the meantime, to ensure continued support, we are displaying the site without styles and javascript. sara reardon is a freelance journalist based in bozeman, montana. you can also search for this author in pubmed google scholar a drug for alzheimer’s disease has won unanimous approval from independent scientists advising the us food and drug administration (fda), bringing the treatment a step closer to use in the clinic. access nature and 54 other nature portfolio journals get nature+, our best value online access subscription $29.99 / 30 days cancel any time receive 51 print issues and online access $199.00 per year only $3.90 per issue rent or buy this article prices vary by article type from$1.95 to$39.95 prices may be subject to local taxes which are calculated during checkout doi: https://doi.org/10.1038/d41586 024 01726 w sims, j. r. et al. jama 330, 512 527 (2023). article pubmed google scholar van dyck, c. h. et al. n. engl. j. med. 388, 9 21 (2023). article pubmed google scholar doran, s. j. & sawyer, r. p. front. neurosci. 18, 1326784 (2024). article pubmed google scholar download references reprints and permissions alzheimer’s drug donanemab: what promising trial means for treatments fda approves alzheimer’s drug lecanemab amid safety concerns this is how an alzheimer’s gene ravages the brain how the brain suppresses fear: mouse study offers path to anxiety treatments news 06 feb 25 engineered nose bacteria sneak drugs into the brain news 06 feb 25 are the internet and ai affecting our memory? what the science says news feature 05 feb 25 revealed: why the fatal huntington’s gene takes so long to cause harm news 17 jan 25 ones to watch: young neuroscientists on the rise nature index 02 oct 24 hybrid protein filaments are a surprise twist in neurodegeneration news & views 02 oct 24 discovery of cellular and molecular mechanisms of tissue repair and regeneration. beijing, china the chinese institutes for medical research (cimr), beijing applications are sought for an assistant professor of bioengineering for the circular bio economy within the college of engineering and architecture dublin, leinster (ie) university college dublin applications are sought for an assistant professor of artificial intelligence in food engineering within the college of engineering and architecture. dublin, leinster (ie) university college dublin the moslehi lab is recruiting highly motivated candidates for a three year post doctoral fellowship san francisco, california ucsf   moslehi lab job title: associate or senior editor, nature health location(s): new york or shanghai   hybrid working application deadline: february 14, 2025 a... new york city, new york (us) springer nature ltd alzheimer’s drug donanemab: what promising trial means for treatments fda approves alzheimer’s drug lecanemab amid safety concerns this is how an alzheimer’s gene ravages the brain an essential round up of science news, opinion and analysis, delivered to your inbox every weekday. sign up for the nature briefing newsletter   what matters in science, free to your inbox daily. nature (nature) issn 1476 4687 (online) issn 0028 0836 (print) © 2025 springer nature limited

how to obtain the latest research advancements in the field of biopharmaceuticals? in the synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. click on the image below to embark on a brand new journey of drug discovery!
supported by the modest benefits of the treatment, donanemab, made by eli lilly, outweigh the risks, the panel concluded unanimously. by gina kolata and pam belluck gina kolata and pam belluck have reported for years on progress and disappointments in alzheimer’s research. a committee of independent advisers to the food and drug administration voted unanimously on monday that the benefits outweigh the risks of the newest experimental drug for alzheimer’s disease. alzheimer’s afflicts more than six million americans. it has no cure, and there is no treatment or lifestyle modification that can restore memory loss or reverse cognitive decline. the drug, made by eli lilly, is donanemab. it modestly slowed cognitive decline in patients in the early stages of the disease but also had significant safety risks, including swelling and bleeding in the brain. the committee concluded, though, that the consequences of alzheimer’s are so dire that even a modest benefit can be worthwhile. the f.d.a. usually follows the advice of the agency’s advisory committees but not always. the drug is based on a long held hypothesis that alzheimer’s disease begins when rough hard balls of amyloid, a protein, pile up in patients’ brains, followed by a cascade of reactions leading to the death of neurons. the idea is to treat alzheimer’s by attacking amyloid, clearing it from the brain. two similar amyloid fighting drugs were approved recently: leqembi, made by eisai and biogen, was approved last year. that drug’s risks and modest benefits are similar to those of donanemab. aduhelm, made by biogen, is the other drug and was approved in 2021 but was discontinued because there was insufficient evidence that it could benefit patients.

 after much debate on the cost benefit analysis and whether the new alzheimer’s drug, donanemab, was worth administering given its modest benefits and side effects, a committee of independent advisers to the us food and drug administration (fda) voted unanimously that the benefits outweigh the risks. the drug, made by eli lilly, had generated much excitement as it slowed cognitive decline in patients in the early stages of the disease. but given that the effects were modest and there were risks such as swelling and bleeding in the brain, the fda withheld approval in march. it had then said that it would have to undergo the scrutiny of an independent advisory committee. that panel has now concluded that when it comes to alzheimer’s, even a modest benefit is worthwhile.